Predicting breast cancer recurrence after extended hormone therapy
Treatments studied
Part of Cancer, Skin clinical trials.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage invasive breast cancer that is estrogen-receptor and/or progesterone-receptor positive
- You finished the usual 5 years of hormone therapy and had no recurrence or spread to other sites (metastasis)
- You are 18 to 70 years old
- You must have at least one high-risk feature: fast-growing marker (Ki-67 ≥ 30%), tumor bigger than 2 cm, cancer in lymph nodes, grade 3 tumor, cancer clot in a blood vessel, or HER2 gene overexpression/amplification
- You have never had another different cancer before, and you haven’t joined another clinical trial recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether taking hormone-blocking pills for longer than 5 years can help lower the risk of breast cancer returning. It is for people who had lymph node involvement and have already completed their initial 5-year treatment without the cancer coming back.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
This study follows people who have had breast cancer come back in the same area after their first surgery. It aims to learn more about local recurrence to improve future treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.